Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells.
Cancer Lett
; 321(2): 120-7, 2012 Aug 28.
Article
en En
| MEDLINE
| ID: mdl-22266098
ABSTRACT
Targeted photosensitizer delivery to EGFR-expressing cells was achieved in the present study using a high purity, targeted photoimmunoconjugate (PIC). When the PDT agent, benzoporphyrin derivative monoacid ring A (BPD) was coupled to an EGFR-targeting antibody (cetuximab), we observed altered cellular localization and selective phototoxicity of EGFR-positive cells, but no phototoxicity of EGFR-negative cells. Cetuximab in the PIC formulation blocked EGF-induced activation of the EGFR and downstream signaling pathways. Our results suggest that photoimmunotargeting is a useful dual strategy for the selective destruction of cancer cells and also exerts the receptor-blocking biological function of the antibody.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Fotoquimioterapia
/
Porfirinas
/
Transducción de Señal
/
Fármacos Fotosensibilizantes
/
Factor de Crecimiento Epidérmico
/
Receptores ErbB
/
Anticuerpos Monoclonales
/
Antineoplásicos
Límite:
Female
/
Humans
Idioma:
En
Revista:
Cancer Lett
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos